脂质代谢重编程对卵巢癌铂耐药影响的研究进展

doi:10.3969/j.issn.1004-616x.2023.04.013

癌变·畸变·突变 ›› 2023, Vol. 35 ›› Issue (4): 316-319.doi: 10.3969/j.issn.1004-616x.2023.04.013

脂质代谢重编程对卵巢癌铂耐药影响的研究进展

崔潆¹, 肖汀², 郭会芹¹

1. 国家癌症中心/国家肿瘤临床医学研究中心/中国医学科学院北京协和医学院肿瘤医院, 病理科, 北京 100021;
2. 国家癌症中心/国家肿瘤临床医学研究中心/中国医学科学院北京协和医学院肿瘤医院, 分子肿瘤学国家重点实验室, 癌发生及预防分子机理北京市重点实验室, 北京 100021

收稿日期:2023-03-28 修回日期:2023-04-23 出版日期:2023-07-30 发布日期:2023-08-04
通讯作者: 郭会芹
作者简介:崔潆，E-mail：cy199910001@163.com。
基金资助:
中国医学科学院临床与转化医学研究专项(2022-I2M-C＆T-B-082)

Received:2023-03-28 Revised:2023-04-23 Online:2023-07-30 Published:2023-08-04

摘要/Abstract

摘要： 卵巢癌是女性致死率最高的恶性肿瘤，晚期患者5年生存率不足50%。以铂类药物为主的化疗是晚期卵巢癌的主要治疗策略，多数患者初期铂类化疗敏感，然而大约80%的铂敏感患者经多次化疗后对铂类产生耐药。与其他上皮性肿瘤不同，卵巢癌的转移方式以向脂肪细胞丰富的大网膜转移为主，这一特殊的转移偏好为寻找脂质代谢相关铂耐药机制的研究提供了新思路。因此，本文综述了胆固醇及脂肪酸两大脂类物质代谢对卵巢癌铂耐药影响的研究进展，以期为改善卵巢癌患者预后，找到规避甚至逆转铂耐药的生物标志物及药物靶点提供新的线索。

关键词: 卵巢癌, 铂耐药, 脂质代谢, 代谢重编程, 生物标志物

中图分类号:

R737.31

崔潆, 肖汀, 郭会芹. 脂质代谢重编程对卵巢癌铂耐药影响的研究进展[J]. 癌变·畸变·突变, 2023, 35(4): 316-319.

参考文献

[1] 潘锋. 铂类药物是妇科恶性肿瘤化疗的基本药物[J]. 中国当代医药, 2021, 28(30): 1-3.
[2] YANG L, XIE H J, LI Y Y, et al. Molecular mechanisms of platinum-based chemotherapy resistance in ovarian cancer (review)[J]. Oncol Rep, 2022, 47(4): 82.
[3] ROSE P G. Ovarian cancer recurrence: is the definition of platinum sensitivity modified by PARPi, bevacizumab or other intervening treatments: a clinical perspective[J]. Cancer Drug Resist, 2022, 5(2): 415-423.
[4] BINJU M, PADILLA M A, SINGOMAT T, et al. Mechanisms underlying acquired platinum resistance in high grade serous ovarian cancer-a mini review[J]. Biochim Biophys Acta Gen Subj, 2019, 1863(2): 371-378.
[5] ICARD P, SHULMAN S, FARHAT D, et al. How the Warburg effect supports aggressiveness and drug resistance of cancer cells-[J]. Drug Resist Updat, 2018, 38: 1-11.
[6] BHATTACHARYA B, MOHD OMAR M F, SOONG R. The Warburg effect and drug resistance[J]. Br J Pharmacol, 2016, 173(6): 970-979.
[7] HUDSON C D, SAVADELIS A, NAGARAJ A B, et al. Altered glutamine metabolism in platinum resistant ovarian cancer[J]. Oncotarget, 2016, 7(27): 41637-41649.
[8] VIALE A, CORTI D, DRAETTA G F. Tumors and mitochondrial respiration: a neglected connection[J]. Cancer Res, 2015, 75(18): 3685-3686.
[9] GHONEUM A, ALMOUSA S, WARREN B, et al. Exploring the clinical value of tumor microenvironment in platinum-resistant ovarian cancer[J]. Semin Cancer Biol, 2021, 77: 83-98.
[10] CHENG C M, GENG F, CHENG X, et al. Lipid metabolism reprogramming and its potential targets in cancer[J]. Cancer Commun, 2018, 38(1): 1-14.
[11] YANG J, ZAMAN M M, VLASAKOV I, et al. Adipocytes promote ovarian cancer chemoresistance[J]. Sci Rep, 2019, 9: 13316.
[12] LEMBERGER L, WAGNER R, HELLER G, et al. Pharmacological inhibition of lipid import and transport proteins in ovarian cancer[J]. Cancers, 2022, 14(23): 6004.
[13] Criscuolo D, Avolio R, Calice G, et al. Cholesterol Homeostasis Modulates Platinum Sensitivity in Human Ovarian Cancer[J]. Cells, 2020, 9(4): 828.
[14] ZHENG L, LI L, LU Y, et al. SREBP2 contributes to cisplatin resistance in ovarian cancer cells[J]. Exp Biol Med Maywood N J, 2018, 243(7): 655-662.
[15] CHANG W C, WANG H C, CHENG W C, et al. LDLR-mediated lipidome-transcriptome reprogramming in cisplatin insensitivity[J]. Endocr Relat Cancer, 2020, 27(2): 81-95.
[16] HUANG X Y, WEI X, QIAO S J, et al. Low density lipoprotein receptor (LDLR) and 3-hydroxy-3-methylglutaryl coenzyme a reductase (HMGCR) expression are associated with platinum-resistance and prognosis in ovarian carcinoma patients[J]. Cancer Manag Res, 2021, 13: 9015-9024.
[17] WU Y F, SI R R, TANG H, et al. Cholesterol reduces the sensitivity to platinum-based chemotherapy via upregulating ABCG2 in lung adenocarcinoma[J]. Biochem Biophys Res Commun, 2015, 457(4): 614-620.
[18] AMOROSO M R, MATASSA D S, AGLIARULO I, et al. TRAP1 downregulation in human ovarian cancer enhances invasion and epithelial-mesenchymal transition[J]. Cell Death Dis, 2016, 7(12): e2522.
[19] DAR S, CHHINA J, MERT I, et al. Bioenergetic adaptations in chemoresistant ovarian cancer cells[J]. Sci Rep, 2017, 7(1): 8760.
[20] TAN Y Y, LI J J, ZHAO G Y, et al. Metabolic reprogramming from glycolysis to fatty acid uptake and beta-oxidation in platinum-resistant cancer cells[J]. Nat Commun, 2022, 13(1): 4554.
[21] NIEMAN K M, KENNY H A, PENICKA C V, et al. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth[J]. Nat Med, 2011, 17(11): 1498-1503.
[22] MUKHERJEE A, CHIANG C Y, DAIFOTIS H A, et al. Adipocyte-induced FABP4 expression in ovarian cancer cells promotes metastasis and mediates carboplatin resistance[J]. Cancer Res, 2020, 80(8): 1748-1761.
[23] LADANYI A, MUKHERJEE A, KENNY H A, et al. Adipocyte-induced CD36 expression drives ovarian cancer progression and metastasis[J]. Oncogene, 2018, 37(17): 2285-2301.
[24] JAYAWARDHANA A M D S, STILGENBAUER M, DATTA P, et al. Fatty acid-like Pt(IV) prodrugs overcome cisplatin resistance in ovarian cancer by harnessing CD36[J]. Chem Commun Camb Engl, 2020, 56(73): 10706-10709.
[25] WEI X, SHI J J, LIN Q H, et al. Targeting ACLY attenuates tumor growth and acquired cisplatin resistance in ovarian cancer by inhibiting the PI3K-AKT pathway and activating the AMPK-ROS pathway[J]. Front Oncol, 2021, 11: 642229.
[26] JHA V, GALATI S, VOLPI V, et al. Discovery of a new ATP-citrate lyase (ACLY) inhibitor identified by a pharmacophore-based virtual screening study[J]. J Biomol Struct Dyn, 2021, 39(11): 3996-4004.
[27] UEDA S M, YAP K L, DAVIDSON B, et al. Expression of fatty acid synthase depends on NAC1 and is associated with recurrent ovarian serous carcinomas[J]. J Oncol, 2010, 2010: 285191.
[28] BAUERSCHLAG D O, MAASS N, LEONHARDT P, et al. Fatty acid synthase overexpression: target for therapy and reversal of chemoresistance in ovarian cancer[J]. J Transl Med, 2015, 13: 146.
[29] UDDIN S, JEHAN Z, AHMED M, et al. Overexpression of fatty acid synthase in Middle Eastern epithelial ovarian carcinoma activates AKT and Its inhibition potentiates cisplatin-induced apoptosis[J]. Mol Med, 2011, 17(7/8): 635-645.
[30] PAPAEVANGELOU E, ALMEIDA G S, BOX C, et al. The effect of FASN inhibition on the growth and metabolism of a cisplatin-resistant ovarian carcinoma model[J]. Int J Cancer, 2018, 143(4): 992-1002.
[31] HUANG D Q, CHOWDHURY S, WANG H, et al. Multiomic analysis identifies CPT1A as a potential therapeutic target in platinum-refractory, high-grade serous ovarian cancer[J]. Cell Rep Med, 2021, 2(12): 100471.
[32] ZHU J R, WU G Y, SONG L B, et al. NKX2-8 deletion-induced reprogramming of fatty acid metabolism confers chemoresistance in epithelial ovarian cancer[J]. EBioMedicine, 2019, 43: 238-252.

脂质代谢重编程对卵巢癌铂耐药影响的研究进展

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	覃熙媛, 朱莹, 李伟滔, 郑晓玲, 梁远秋. 上皮性卵巢癌组织中FoxM1的表达及其临床意义[J]. 癌变·畸变·突变, 2023, 35(4): 273-278.
[2]	刘瑞雪, 张力为. 腺苷酸活化蛋白激酶在哈萨克族食管鳞癌组织中的表达及意义[J]. 癌变·畸变·突变, 2023, 35(4): 285-291.
[3]	陈双, 彭中芮, 吴桢雯, 郭东北, 孙美君, 李蕾. 明日叶查尔酮对小鼠急性酒精性肝损伤的保护作用[J]. 癌变·畸变·突变, 2023, 35(2): 95-101.
[4]	谭健华, 赖姚圳, 唐丽华, 周莉. 2种不同疗法对晚期上皮性卵巢癌的疗效及患者预后影响因素分析[J]. 癌变·畸变·突变, 2023, 35(2): 131-138.
[5]	张海智, 温晓芬, 黄彬亮, 林慧, 薛文武, 曾德, 林丹霞. 溶质载体超家族50蛋白在乳腺癌中的表达及其临床意义[J]. 癌变·畸变·突变, 2022, 34(5): 373-377.
[6]	王婷, 张雯雯, 张永欣, 曾勇, 王俊玲, 李成云. miR-101基因簇与食管癌发病风险的病例对照研究[J]. 癌变·畸变·突变, 2022, 34(4): 273-278.
[7]	兰尤, 陈圆圆, 林忠宁, 林育纯. 病毒致癌过程中的线粒体糖酵解代谢重编程机制研究进展[J]. 癌变·畸变·突变, 2021, 33(6): 470-474.
[8]	马亚南, 吴楠, 金焰. 肿瘤微环境与卵巢癌化疗耐药机制的研究进展[J]. 癌变·畸变·突变, 2021, 33(5): 393-395,400.
[9]	张玉领, 陈培. 环状RNA在食管癌中的研究进展[J]. 癌变·畸变·突变, 2021, 33(3): 241-245.
[10]	徐海明, 刘科良, 郝艳星, 汪岭, 刘志宏, 德小明. 生物标志物的联合检测对矽肺早期辅助诊断的价值[J]. 癌变·畸变·突变, 2020, 32(5): 395-397,401.
[11]	赵骅, 陆雪, 蔡恬静, 李爽, 田梅, 刘青杰. 基于代谢组学方法筛选大鼠血浆辐射敏感代谢物[J]. 癌变·畸变·突变, 2020, 32(3): 166-170,176.
[12]	田雪蕾, 封江彬, 田梅, 刘青杰. 甲基化芯片检测电离辐射诱导人外周血淋巴细胞DNA甲基化水平的变化[J]. 癌变·畸变·突变, 2019, 31(6): 434-439.
[13]	万树泉, 魏丽军, 王福花, 曾勇. miR-200b-3p和PAK2 mRNA在耐药卵巢癌组织中的表达及其临床意义[J]. 癌变·畸变·突变, 2019, 31(3): 216-221.
[14]	姜晓旭, 郑义鹏, 赵九洲, 李明哲, 朱敬朴, 王欣, 李永奇, 海春旭, 于卫华. M1型巨噬细胞糖代谢重编程机制及其在炎症启动中的关键作用[J]. 癌变·畸变·突变, 2019, 31(1): 79-81,85.
[15]	郑剑, 蓝涛, 刘威, 邓荣霞, 李培茂, 张艳芳, 刘建军. 三氯乙烯药疹样皮炎患者血清miRNAs差异表达谱分析[J]. 癌变·畸变·突变, 2016, 28(6): 468-471.